Zacks Research Has Bullish Estimate for ESPR FY2027 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Analysts at Zacks Research lifted their FY2027 earnings per share (EPS) estimates for Esperion Therapeutics in a research report issued to clients and investors on Tuesday, May 27th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings of $0.10 per share for the year, up from their previous forecast of $0.09. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share.

ESPR has been the topic of several other reports. The Goldman Sachs Group cut their price target on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. HC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research note on Friday, April 25th. Needham & Company LLC reduced their price target on Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, JMP Securities restated a "market outperform" rating and issued a $4.00 price objective (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $6.25.

Esperion Therapeutics Stock Up 6.3%

Shares of Esperion Therapeutics stock traded up $0.05 during trading on Thursday, reaching $0.90. The company's stock had a trading volume of 4,462,737 shares, compared to its average volume of 5,451,976. Esperion Therapeutics has a 1-year low of $0.69 and a 1-year high of $3.94. The company has a market cap of $178.97 million, a price-to-earnings ratio of -1.41 and a beta of 0.75. The company has a 50-day simple moving average of $1.00 and a two-hundred day simple moving average of $1.74.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The company had revenue of $65.00 million for the quarter, compared to analysts' expectations of $54.97 million.

Hedge Funds Weigh In On Esperion Therapeutics

A number of large investors have recently added to or reduced their stakes in ESPR. Wasatch Advisors LP increased its stake in shares of Esperion Therapeutics by 4.9% during the fourth quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company's stock worth $53,861,000 after purchasing an additional 1,136,245 shares in the last quarter. Two Sigma Advisers LP increased its stake in Esperion Therapeutics by 0.4% during the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company's stock worth $7,956,000 after buying an additional 16,100 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in shares of Esperion Therapeutics by 48.6% during the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock valued at $6,862,000 after acquiring an additional 1,020,243 shares during the last quarter. Nuveen LLC purchased a new position in shares of Esperion Therapeutics in the first quarter valued at approximately $4,446,000. Finally, JPMorgan Chase & Co. lifted its position in shares of Esperion Therapeutics by 18.6% in the fourth quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company's stock valued at $5,399,000 after acquiring an additional 385,099 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.